keyword
MENU ▼
Read by QxMD icon Read
search

Blood test for lung cancer

keyword
https://www.readbyqxmd.com/read/28432274/sensitive-detection-of-viable-circulating-tumor-cells-using-a-novel-conditionally-telomerase-selective-replicating-adenovirus-in-non-small-cell-lung-cancer-patients
#1
Shinsaku Togo, Nobuyoshi Katagiri, Yukiko Namba, Miniwan Tulafu, Kumi Nagahama, Kotarou Kadoya, Kazuya Takamochi, Siaki Oh, Kenji Suzuki, Fuminori Sakurai, Hiroyuki Mizuguchi, Yasuo Urata, Kazuhisa Takahashi
Circulating tumor cells (CTCs) have a crucial role in the clinical outcome of cancer patients. Detection of non-small cell lung cancer (NSCLC) using an antibody against epithelial cell adhesion molecule (EpCAM) in captured CTCs has low sensitivity; the loss of epithelial markers leads to underestimation of CTCs with mesenchymal phenotype. We propose a new approach for detection of viable CTCs, including those with epithelial-mesenchymal transition status (EMT-CTCs), using the new telomerase-specific replication-selective adenovirus (OBP-1101), TelomeScan F35...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28427160/biomarker-analysis-of-the-phase-3-torch-trial-for-first-line-erlotinib-versus-chemotherapy-in-advanced-non-small-cell-lung-cancer-patients
#2
Lucia Kim, Mauro Saieg, Massimo Di Maio, Ciro Gallo, Charles Butts, Fortunato Ciardiello, Ronald Feld, Dengxiao Cheng, Vittorio Gebbia, Marco Angelo Burgio, Yasmin Alam, Simona Signoriello, Antonio Rossi, Natasha Leighl, Paolo Maione, Alessandro Morabito, Geoffrey Liu, Ming-Sound Tsao, Francesco Perrone, Cesare Gridelli
BACKGROUND: The TORCH phase III trial compared the efficacy of first-line erlotinib followed by chemotherapy at progression (experimental arm) with the reverse sequence (standard arm) in unselected advanced non-small cell lung cancer (NSCLC) patients. Here we report biomarker analyses. METHODS: EGFR and KRAS mutation, expression of EGFR family members and of cMET and PTEN and EGFR and ABCG2 germline polymorphisms were tested on tumor tissue or blood samples to either confirm previously proposed predictive role or describe it in an explorative setting...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28419195/plasma-ctdna-ras-mutation-analysis-for-the-diagnosis-and-treatment-monitoring-of-metastatic-colorectal-cancer-patients
#3
J Vidal, L Muinelo, A Dalmases, F Jones, D Edelstein, M Iglesias, M Orrillo, A Abalo, C Rodríguez, E Brozos, Y Vidal, S Candamio, F Vázquez, J Ruiz, M Guix, L Visa, V Sikri, J Albanell, B Bellosillo, R López, C Montagut
Background: RAS assessement is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our study aims to evaluate the use of ctDNA as an alternative determining baseline RAS status and subsequent monitoring of RAS mutations during therapy as a component of routine clinical practice...
April 13, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28412747/selenomethionine-and-methyl-selenocysteine-multiple-dose-pharmacokinetics-in-selenium-replete-men
#4
James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, Kristina E Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan
According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer...
February 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28411113/restrictive-spirometry-pattern-is-associated-with-increased-arterial-stiffness-in-men-and-women
#5
I-Hsuan Wu, Zih-Jie Sun, Feng-Hwa Lu, Yi-Ching Yang, Chieh-Ying Chou, Chih-Jen Chang, Jin-Shang Wu
BACKGROUND: There is growing evidence that pulmonary function impairment has been found to be related to cardiovascular events and death. Some studies showed that the level of forced vital capacity (FVC) was negatively related to arterial stiffness, but most studies were confined to males and none of them examined the association of the presence of restrictive spirometry pattern with arterial stiffness. Therefore, this study aimed to investigate the association of restrictive spirometry pattern with arterial stiffness by gender...
April 11, 2017: Chest
https://www.readbyqxmd.com/read/28405516/assessment-of-tumor-infiltrating-tcrv%C3%AE-9v%C3%AE-2-%C3%AE-%C3%AE-lymphocyte-abundance-by-deconvolution-of-human-cancers-microarrays
#6
Marie Tosolini, Frédéric Pont, Mary Poupot, François Vergez, Marie-Laure Nicolau-Travers, David Vermijlen, Jean-Emmanuel Sarry, Francesco Dieli, Jean-Jacques Fournié
Most human blood γδ cells are cytolytic TCRVγ9Vδ2(+) lymphocytes with antitumor activity. They are currently investigated in several clinical trials of cancer immunotherapy but so far, their tumor infiltration has not been systematically explored across human cancers. Novel algorithms allowing the deconvolution of bulk tumor transcriptomes to find the relative proportions of infiltrating leucocytes, such as CIBERSORT, should be appropriate for this aim but in practice they fail to accurately recognize γδ T lymphocytes...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28393575/using-circulating-cell-free-dna-to-monitor-personalized-cancer-therapy
#7
Michael Oellerich, Ekkehard Schütz, Julia Beck, Philipp Kanzow, Piers N Plowman, Glen J Weiss, Philip D Walson
High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time molecular monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be especially useful when tumor tissue is unavailable or insufficient for testing. For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied...
April 10, 2017: Critical Reviews in Clinical Laboratory Sciences
https://www.readbyqxmd.com/read/28387927/multimodal-lung-cancer-screening-using-the-italung-biomarker-panel-and-low-dose-computed-tomography-results-of-the-italung-biomarker-study
#8
Francesca Maria Carozzi, Simonetta Bisanzi, Laura Carrozzi, Fabio Falaschi, Andrea Lopes Pegna, Mario Mascalchi, Giulia Picozzi, Marco Peluso, Cristina Sani, Luana Greco, Cristina Ocello, Eugenio Paci
Asymptomatic high-risk subjects, randomized in the intervention arm of the ITALUNG trial (1406 screened for lung cancer), were enrolled for the ITALUNG biomarker study (n = 1356), in which samples of blood and sputum were analysed for plasma DNA quantification (cut off 5ng/ml), loss of heterozygosity and microsatellite instability. The ITALUNG biomarker panel (IBP) was considered positive if at least one of the two biomarkers included in the panel was positive. Subjects with and without lung cancer diagnosis at the end of the screening cycle with LDCT (n = 517) were evaluated...
April 7, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28368960/ubiquitinated-proteins-isolated-from-tumor-cells-are-efficient-substrates-for-antigen-cross-presentation
#9
Guangjie Yu, Tarsem Moudgil, Zhihua Cui, Yongbin Mou, Lixin Wang, Bernard A Fox, Hong-Ming Hu
We have previously shown that inhibition of the proteasome causes defective ribosomal products to be shunted into autophagosomes and subsequently released from tumor cells as defective ribosomal products in Blebs (DRibbles). These DRibbles serve as an excellent source of antigens for cross-priming of tumor-specific T cells. Here, we examine the role of ubiquitinated proteins (Ub-proteins) in this pathway. Using purified Ub-proteins from tumor cells that express endogenous tumor-associated antigen or exogenous viral antigen, we tested the ability of these proteins to stimulate antigen-specific T-cell responses, by activation of monocyte-derived dendritic cells generated from human peripheral blood mononuclear cells...
March 31, 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28335271/distribution-of-iron-oxide-core-titanium-dioxide-shell-nanoparticles-in-vx2-tumor-bearing-rabbits-introduced-by-two-different-delivery-modalities
#10
Tamer Refaat, Derek West, Samar El Achy, Vamsi Parimi, Jasmine May, Lun Xin, Kathleen R Harris, William Liu, Michael Beau Wanzer, Lydia Finney, Evan Maxey, Stefan Vogt, Reed A Omary, Daniele Procissi, Andrew C Larson, Tatjana Paunesku, Gayle E Woloschak
This work compares intravenous (IV) versus fluoroscopy-guided transarterial intra-catheter (IC) delivery of iron oxide core-titanium dioxide shell nanoparticles (NPs) in vivo in VX2 model of liver cancer in rabbits. NPs coated with glucose and decorated with a peptide sequence from cortactin were administered to animals with developed VX2 liver cancer. Two hours after NPs delivery tumors, normal liver, kidney, lung and spleen tissues were harvested and used for a series on histological and elemental analysis tests...
August 3, 2016: Nanomaterials
https://www.readbyqxmd.com/read/28331344/adverse-prognostic-impact-of-tgfb1-t869c-polymorphism-in-non-small-cell-lung-cancer
#11
Yulan Sang, Xin Bi, Yan Liu, Wei Zhang, Dongjie Wang
Previously, several polymorphisms in TGFB1 have been identified in non-small-cell lung cancer (NSCLC), and the variants, C-509T, T869C, and G915C, have been demonstrated to associate with higher circulating levels of TGF-β1. However, little is known about the prognostic value of TGF-β1 polymorphisms in cancers. In this study, by genotyping the TGF-β1 T869C polymorphism in a total of 261 patients with NSCLC using DNA from blood lymphocytes, we first found that NSCLC patients, especially those with allele C carriers, had significantly higher serum TGF-β1 levels than healthy individuals...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28316059/prevention-of-tumour-cell-apoptosis-associated-with-sustained-protein-kinase-b-phosphorylation-is-more-sensitive-to-regulation-by-insulin-signalling-than-stimulation-of-proliferation-and-extracellular-signal-regulated-kinase
#12
Christoph Schmid, Claudia Ghirlanda, Markus Niessen
Insulin controls blood glucose while insulin-like growth factor (IGF) 1 is an important growth factor. Interestingly, both hormones have overlapping bioactivities and can activate the same intracellular signal transduction cascades. Growth control (mainly by IGF1) and metabolic function (predominantly by insulin) are believed to depend on activation of extracellular signal-regulated kinases (ERKs) 1/2 and protein kinase B (Akt/PKB), respectively. Therefore, insulin analogues that are used to normalize blood glucose are tested for their ability to preferentially activate Akt/PKB but not ERK1/2 and mitogenesis...
March 18, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28289866/the-role-of-circulating-tumor-cells-in-evaluation-of-prognosis-and-treatment-response-in-advanced-non-small-cell-lung-cancer
#13
Jia Zhou, Fei Dong, Fang Cui, Rui Xu, Xiaokui Tang
PURPOSE: Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict the prognosis and treatment response. This study investigated whether circulating tumor cells (CTCs) detectable could reminder high risk of distant metastasis, provide prognostic information, and early indicate the response to the conventional therapy in patients with advanced NSCLC. PATIENTS AND METHODS: In this single-center prospective study, blood samples for CTC analysis were obtained from 59 patients with previously untreated, stage III or IV NSCLC both before and after administration of two cycles of chemotherapy...
March 13, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28284200/detection-in-blood-of-autoantibodies-to-tumour-antigens-as-a-case-finding-method-in-lung-cancer-using-the-earlycdt%C3%A2-lung-test-ecls-study-protocol-for-a-randomized-controlled-trial
#14
F M Sullivan, Eoghan Farmer, Frances S Mair, Shaun Treweek, Denise Kendrick, Cathy Jackson, Chris Robertson, Andrew Briggs, Colin McCowan, Laura Bedford, Ben Young, Kavita Vedhara, Stephanie Gallant, Roberta Littleford, John Robertson, Herb Sewell, Alistair Dorward, Joseph Sarvesvaran, Stuart Schembri
BACKGROUND: Lung cancer is the most common cause of cancer related death worldwide. The majority of cases are detected at a late stage when prognosis is poor. The EarlyCDT®-Lung Test detects autoantibodies to abnormal cell surface proteins in the earliest stages of the disease which may allow tumour detection at an earlier stage thus altering prognosis. The primary research question is: Does using the EarlyCDT®-Lung Test to identify those at high risk of lung cancer, followed by X-ray and computed tomography (CT) scanning, reduce the incidence of patients with late-stage lung cancer (III & IV) or unclassified presentation (U) at diagnosis, compared to standard practice? METHODS: A randomised controlled trial of 12 000 participants in areas of Scotland targeting general practices serving patients in the most deprived quintile of the Scottish Index of Multiple Deprivation...
March 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28251125/the-first-liquid-biopsy-test-approved-is-it-a-new-era-of-mutation-testing-for-non-small-cell-lung-cancer
#15
Dorota Kwapisz
Specific mutations in epidermal growth factor receptor (EGFR) gene are predictive for response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients (NSCLC). According to international guidelines, the molecular testing in patients with advanced NSCLC of a non-squamous subtype is recommended. However, obtain a tissue sample could be challenging. Liquid biopsy allows to determine patients suitable for EGFR-targeted therapy by analysis of circulating-free tumor DNA (cfDNA) in peripheral blood samples and might replace tissue biopsy...
February 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28207548/egfr-mutation-testing-in-blood-for-guiding-egfr-tyrosine-kinase-inhibitor-treatment-in-patients-with-nonsmall-cell-lung-cancer-a-protocol-for-systematic-review-and-meta-analysis
#16
REVIEW
Jin-Qiu Yuan, Yue-Lun Zhang, Hai-Tao Li, Chen Mao
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing in tumor tissue is now a common practice in selecting non-small cell lung cancer (NSCLC) patients for EGFR tyrosine kinase inhibitor (TKI) treatment. However, tumor tissues are often absent or insufficient for the testing. Blood is a potential substitute providing a noninvasive, easily accessible and repeatedly measureable source of genotypic information. However which is the best blood EGFR mutation testing method remains unclear...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28199364/coagulation-profile-in-patients-undergoing-video-assisted-thoracoscopic-lobectomy-a-randomized-controlled-trial
#17
Thomas Decker Christensen, Henrik Vad, Søren Pedersen, Kåre Hornbech, Nora Elisabeth Zois, Peter B Licht, Mads Nybo, Anne-Mette Hvas
BACKGROUND: Knowledge about the impact of Low-Molecular-Weight Heparin (LMWH) on the coagulation system in patients undergoing minimal invasive lung cancer surgery is sparse. The aim of this study was to assess the effect of LMWH on the coagulation system in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer. METHODS: Sixty-three patients diagnosed with primary lung cancer undergoing VATS lobectomy were randomized to either subcutaneous injection with dalteparin (Fragmin®) 5000 IE once daily or no intervention...
2017: PloS One
https://www.readbyqxmd.com/read/28196386/-liquid-biopsy-detection-of-molecular-markers-for-treatment-decisions-in-lung-cancer
#18
W M Brückl, R M Wirtz, T Bertsch, J H Ficker, A Jung
Personalized, individualized, targeted therapy has successfully found entrance in the palliative treatment of lung cancer as they enable a personalized and individualized strategy going ahead with biomarker testing. Due to the crescending amount of predictive molecular and immunhistochemical analyses at different time points during therapy the need for more and actual tumor tissue increases; however these samples cannot always be obtained without major discomfort for the patients. Therefore, analyses from blood, the so called "liquid biopsy", is an alternative or additional method...
March 2017: Pneumologie
https://www.readbyqxmd.com/read/28194229/circulating-and-tissue-biomarkers-in-early-stage-non-small-cell-lung-cancer
#19
Caterina Fumagalli, Fabrizio Bianchi, Paola Rafaniello Raviele, Davide Vacirca, Giovanni Bertalot, Cristiano Rampinelli, Matteo Lazzeroni, Bernardo Bonanni, Giulia Veronesi, Nicola Fusco, Massimo Barberis, Elena Guerini-Rocco
OBJECTIVE: We sought to characterise circulating and tissue tumour biomarkers of patients who developed early-stage non-small cell lung cancer (NSCLC) during long-term follow-up of a chemoprevention trial (NCT00321893). MATERIALS AND METHODS: Blood and sputum samples were collected from 202 high-risk asymptomatic individuals with CT-detected stable lung nodules. Real-time PCR was performed on plasma to quantify free circulating DNA. Baseline serum was investigated with a previously validated test based on 13 circulating miRNAs (miR-Test)...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28186469/blood-based-nucleic-acid-biomarkers-as-a-potential-tool-to-determine-radiation-therapy-response-in-non-small-cell-lung-cancer
#20
Christopher R Deig, Marc S Mendonca, Tim Lautenschlaeger
Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20% lung cancer specific mortality benefit; however, widespread implementation is estimated to add $1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs), have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT...
February 10, 2017: Radiation Research
keyword
keyword
24482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"